本资产评估报告依据中国资产评估准则编制 云南白药集团中药资源有限公司拟收购安 国市聚药堂药业有限公司 100%股权涉及的 安国市聚药堂药业有限公司股东全部权益 价值项目 资产评估报告 天兴评报字[2025]第 1013 号 出业资产计 ASSETSAPPRAISAL 二〇二五年八月十四日 中国资产评估协会 资产评估业务报告备案回执 | 报告编码: | 1111020141202500956 | | --- | --- | | 合同编号: | HT1042025184 | | 报告类型: | 法定评估业务资产评估报告 | | 报告文号: | 天兴评报字[2025]第1013号 | | 报告名称: | 元南白药集团中药资源有限公司拟收购安国市聚药堂药业有限公 司100%股权涉及的安国市聚药堂药业有限公司股东全部权益价值 项目资产评估报告 | | 评估结论: | 678,641,000.00元 | | 评估报告日: | 2025年08月14日 | | 评估机构名称: | 北京天健兴业资产评估有限公司 | | | 正式会员 编号: 1110108 彭洁 (资产评估师) | | 答名人员: | 正式会员 编号: 112 ...

安国市聚药堂药业有限公司 财务报表及审计报告 2025 年 1 月 1 日至 3 月 31 日止期间及 2024 年度 安国市聚药堂药业有限公司 财务报表及审计报告 2025 年 1 月 1 日至 3 月 31 目止期间及 2024 年度 | 内容 | 页码 | | --- | --- | | 审计报告 | 1 - 3 | | 资产负债表 | 4 - 5 | | 利润表 | б | | 现金流量表 | 7 | | 所有者权益变动表 | 8 | | 财务报表附注 | 9 -- 43 | Deloitte. 三、强调事项 -- 编制基础 我们提醒财务报表使用者关注财务报表附注二对编制基础的说明。聚药堂的财务报表仅为 云南白药集团股份有限公司拟投资聚药堂之目的编制。因此,财务报表可能不适用于其他用 途。我们的报告仅用于上述目的,未经本所书面同意,不得用于其他任何目的。本段内容不影 响已发表的审计意见。 WorldClass 智启非凡 审计报告 德师报(审)字(25)第 S00633 号 (第1页,共3页) 云南白药集团股份有限公司董事会: 一、审计意见 我们审计了安国市聚药堂药业有限公司(以下简称"聚药堂")的财务 ...

Group 1 - The company announced that its wholly-owned subsidiary, Yunnan Baiyao Group Traditional Chinese Medicine Resources Co., Ltd., plans to acquire 100% equity of An Guo Shi Ju Yao Tang Pharmaceutical Co., Ltd. for 660 million yuan in cash [1] - The acquisition aims to respond to the high-quality development requirements of the traditional Chinese medicine industry in Yunnan Province and align with the company's strategic development goals [1] - The acquisition is expected to enhance the sales of traditional Chinese medicine materials within Yunnan Province, accelerate the national business layout of Yunnan Baiyao, achieve scale expansion, and improve the collaborative efficiency of the traditional Chinese medicine industry chain [1] Group 2 - Ju Yao Tang specializes in the production and sales of traditional Chinese medicine pieces, toxic traditional Chinese medicine pieces, directly consumable traditional Chinese medicine pieces, and formula granules, demonstrating stable and sustainable profitability [1]

证券代码:000538 证券简称:云南白药 公告编号:2025-25 云南白药集团股份有限公司 关于对安国市聚药堂药业有限公司进行全资收购的公告 重要提示：本公司及董事会全体成员保证信息披露内容的真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 云南白药集团股份有限公司（以下简称"云南白药"或"公司"）于 2025年8月15日召开第十届董事会2025年第四次会议，审议通过《关于对 安国市聚药堂药业有限公司进行全资收购的议案》，为响应云南省人民政 府提出的高质量发展云南省中药材产业的要求，结合公司自身战略发展目 标，为更好带动云南省内中药材销售，更快推动云南白药相关业务布局全 国，实现规模扩张，提升中药材产业链协同效率，公司全资子公司云南白 药集团中药资源有限公司（以下简称"中药资源公司"）将以现金方式收 购安国市聚药堂药业有限公司（以下简称"目标公司"或"聚药堂"） 100%股权，股权转让对价总额为人民币66,000万元，交易完成后，中药资 源公司将持有聚药堂100%股权。具体情况如下： 一、交易概述 云南白药全资子公司中药资源公司与聚药堂现股东马新宏、马占江、 张双、石跃欣、石光（以下简称"现股东" ...

股票代码：000538 股票简称：云南白药 公告编号：2025-24 云南白药集团股份有限公司 关于拟变更公司2025年度审计机构 （含内部控制审计）的公告 重要提示：本公司及其董事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 1.前任会计师事务所：中审众环会计师事务所（特殊普通合伙）（以下简 称"中审众环"）。 2.拟聘任会计师事务所：天健会计师事务所（特殊普通合伙）（以下简称 "天健事务所"）。 3.变更会计师事务所的原因：鉴于中审众环已为公司服务满 9 年，根据财 政部、国务院国有资产监督管理委员会、中国证券监督管理委员会颁布的《国 有企业、上市公司选聘会计师事务所管理办法》（财会〔2023〕4 号）的相关 规定，综合考虑云南白药集团股份有限公司（以下简称"公司"）的发展以及 管理需求等情况，经邀请招标，公司拟变更 2025 年度会计师事务所，聘任天 健事务所为公司 2025 年度审计机构（含内部控制审计）。 1 / 6 公司于 2025 年 8 月 15 日召开第十届董事会 2025 年第四次会议，审议通 过了《关于变更公司 2025 年度审计机构（含内部控制审 ...

云南白药集团股份有限公司（以下简称"公司"或"云南白药"）第十 届董事会 2025 年第四次会议（以下简称"会议"）于 2025 年 8 月 15 日以 通讯表决的方式召开，本次会议通知于 2025 年 8 月 11 日以书面、邮件方 式发出，应出席董事 11 名，实际出席董事 11 名。本次会议的召集、召开程 序符合《中华人民共和国公司法》《公司章程》的相关规定，会议合法有效。 会议审议通过如下议案： 一、审议通过《关于公司董监事等核心人员 2024 年短期激励分配执行 的议案》 根据 2019 年 10 月 29 日公司 2019 年第三次临时股东大会审议通过的 《云南白药集团股份有限公司董监事等核心人员薪酬与考核管理办法》的 相关规定，公司 2024 年业绩达到年度目标，经公司董事会薪酬与考核委员 会审议，公司董事会核准公司董监事等核心人员 2024 年短期激励的分配方 案并予执行。 股票代码：000538 股票简称：云南白药 公告编号：2025-23 云南白药集团股份有限公司 第十届董事会 2025 年第四次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性 ...

Core Insights - The Yunnan Provincial Drug Administration conducted a series of inspections on medical device manufacturers and clinical trial institutions, revealing compliance issues that require rectification within a specified timeframe [2][3][4] Group 1: Medical Device Manufacturers - A total of 42 medical device manufacturers were inspected, all of which were found to be compliant but required limited-time rectification [3][4] - Specific companies under scrutiny include Yunnan Opus Medical Technology Co., Ltd., Kunming Qimei Dental Technology Co., Ltd., and Yunnan Beitaini Health Technology Co., Ltd., among others [3][4] Group 2: Clinical Trial Institutions - Nine clinical trial institutions were inspected, all deemed compliant but also required to implement rectifications within a limited timeframe [4] - Institutions inspected include Zhaotong Traditional Chinese Medicine Hospital, Xiangyun County People's Hospital, and Yunnan Provincial Tumor Hospital [4]

Group 1 - The Chinese medicine ETF (159647) has seen a continuous inflow of funds, totaling 30.03 million yuan over the past five days, with a net inflow of 22.14 million yuan since August [1] - The China Traditional Chinese Medicine Index (930641) has increased by 0.77%, with notable gains from companies such as Kang En Bei (600572) up 5.41% and Zhong Sheng Pharmaceutical (002317) up 4.80% [1] - The release of the "Chinese Atrial Fibrillation Management Guidelines (2025)" recommends the use of Tongluo drugs, specifically the Shen Song Yang Xin capsule, for maintaining sinus rhythm in paroxysmal atrial fibrillation [1] Group 2 - Jiang Hai Securities highlights that the labeling of expiration dates on traditional Chinese medicine pieces enhances product transparency, boosting consumer confidence and potentially expanding the market [2] - The top ten weighted stocks in the China Traditional Chinese Medicine Index account for 54.58% of the index, with major companies including Yunnan Baiyao (000538) and Tong Ren Tang (600085) [2] - The Chinese medicine ETF closely tracks the China Traditional Chinese Medicine Index, which reflects the overall performance of listed companies involved in the production and sale of traditional Chinese medicine [2]

2025年8月11日，双方自行和解或者投诉人撤回投诉。处理部门为：昆明市呈贡区市场监督管理局。 8月11日，根据全国12315消费投诉信息公示，云南白药集团股份有限公司新增投诉。 根据投诉信息，2025年06月12日，消费者蔡**（手机尾号 0712，用户ID ****1038）反映其于2025年06 月12日在其他平台（云南白药养元青）通过网购购买洗发品。可能存在质量->其他质量问题，要求退 货，赔偿损失。 天眼查商业履历信息显示，云南白药集团股份有限公司成立于1993年11月30日，位于云南省昆明市呈贡 区云南白药街3686号，是一家以从事医药制造业为主的企业，企业注册资本104139.9718万人民币，法 定代表人为董明。 ...

Industry Overview - The steam eye mask industry is experiencing significant growth due to increasing eye fatigue caused by prolonged use of electronic devices. The market size in China is projected to reach 1.22 billion yuan in 2024, representing an 18.4% year-on-year increase [1][12]. - The rise in consumer interest in personal care products, especially post-pandemic, has made steam eye masks a popular choice for alleviating eye fatigue and dryness, as well as aiding sleep [1][12]. Product Types and Materials - Steam eye masks can be categorized into powder type and sheet type based on their heating methods. The powder type uses iron powder, which may lead to uneven heating, while the sheet type provides more uniform heat and is generally safer for users [4]. - Common materials used in steam eye masks include non-woven fabric, cotton, and bamboo charcoal fiber. Non-woven fabric is preferred for its softness, breathability, and hygiene, while bamboo charcoal fiber offers excellent moisture absorption and antibacterial properties [4][8]. Industry Supply Chain - The upstream of the steam eye mask industry includes raw materials such as fabrics, rubber, silicone, non-woven fabric, heating elements, and essential oils. The quality and cost of these materials directly impact product quality and pricing [6]. - The midstream focuses on product development, production, quality control, and packaging, while the downstream encompasses sales channels including online platforms and physical retail stores [6]. Market Distribution - The market for steam eye masks is primarily concentrated in first-tier cities, which account for 45% of the market share. Second-tier and third-tier cities follow with 30% and 25% respectively. The demand in lower-tier cities is expected to grow as income levels rise [14]. Competitive Landscape - The steam eye mask market is dominated by several large companies, including Yunnan Baiyao, Renhe, and Kang En Bei, which leverage strong brand influence and extensive sales channels. Emerging brands are also gaining traction through differentiated strategies [15][19]. Sales Channels - Online sales channels, particularly e-commerce platforms like Tmall and JD.com, have become the primary sales avenues for steam eye masks due to their convenience and extensive product information. The e-commerce sector in China is projected to reach 46.41 trillion yuan in 2024, reflecting a 3.90% year-on-year increase [10]. Industry Trends - Technological innovation is a key driver for the steam eye mask industry, with advancements in heating technology expected to enhance product safety and comfort [21]. - There is a growing emphasis on the use of eco-friendly materials in product development, aligning with increasing consumer awareness of environmental issues [23]. - Market demand is anticipated to diversify and segment further, with companies expected to introduce specialized products catering to different consumer groups, such as children and the elderly [24].